Faɗin ido ga kowane nau'in EB

Masu binciken suna haɓaka digon ido da aka yi daga gellan danko, ƙari na abinci (E418). Bakteriya ne ke yin ta kuma ana amfani da ita maimakon gelatin (samfurin dabba) a cikin kayan zaki na vegan. Ta hanyar narkewa daban-daban na gellan danko a cikin ruwa, za su iya yin digon ido na 'fluid-gel' wanda ke da sauƙin shafa kuma yana iya zama mafi kyau fiye da yadda ake samu a yanzu wajen hana tabon ido wanda ke haifar da ciwo da matsalolin hangen nesa ga mutane da yawa. mutanen da ke zaune tare da EB.

Jagoran bincike:

Liam Farfesa ne na Biomaterials, ya nada ƙaramin farfesa a tarihin Jami'ar Birmingham yana da shekaru 32, kuma Daraktan-Daraktan Cibiyar Fasaha ta Kiwon Lafiya a Jami'ar Birmingham. Ya kafa rikodin rikodi mai ƙarfi na haɓaka kayan tarihi / fasaha har zuwa aikace-aikacen asibiti. Wannan ya haifar da kewayon ayyuka masu tasiri (ciki har da fiye da 7000 ƙididdiga daga fiye da 150 takardu; H-index of 45) da kuma samar da kan 20 patents a cikin filin. Ya kasance yana da hannu wajen tara> £30m daga majalisun bincike (EPSRC, BBSRC, MRC, NC3Rs), NIHR da kungiyoyin agaji (Barka da zuwa), kuma a halin yanzu yana zaune akan bangarorin DPFS da i4i, kuma akan EPSRC Strategic Advisory Team for Healthcare. Fasaha. Shi ne zai dauki nauyin gudanar da aikin.

Masu bincike:

Dokta Richard Moakes malami ne a cikin kayan kiwon lafiya kuma manajan samar da GMP a cikin Ci gaban Therapies Facility. Richard yana da tushe mai ƙarfi a cikin abubuwa masu laushi kuma ya yi aiki da yawa tare da zubar da ido, bayan da ya ƙirƙira, kuma ya kera shi don gwaji na asibiti. Saboda haka, zai ba da shawara game da masana'anta da sake rarraba samfurin ido na ido.

Farfesa Anthony Metcalfe Farfesan Masana'antu ne na warkar da raunuka a Jami'ar Birmingham. Yana da gogewar sama da shekaru 25 na haɓakawa da kasuwancin warkar da rauni da rage tabo waɗanda ke ɗaukar waɗannan har zuwa Gwajin asibiti na Mataki na III. A tsawon aikinsa, fassarar hanyoyin kwantar da hankali, ya sami ci gaba mai ƙarfi a cikin kasuwanci da tsari. Don haka, zai ba da shawara da taimako a cikin hanyar fassarar fasaha da fassarar ta gaba.

Farfesa Adrian Heagerty mashawarcin likitan fata ne kuma farfesa mai daraja a cikin Asibitocin Jami'ar NHS Trust a Birmingham. Adrian shine jagorar likitancin Midlands da Arewacin Ingila, a cikin Sabis na Adult na Bullosa na ƙasa. Ya shiga cikin kulawa da bincike a cikin EB tsawon shekaru 35. Zai taimaka wajen daidaita haɗin gwiwar haƙuri da jama'a, saboda a halin yanzu yana hulɗa da ca. 320 marasa lafiya tare da EB, kuma suna ba da ƙwarewa game da cutar.

Ms Saaeha Rauz mai karatu ce a Fassarar Ophthalmology a Jami'ar Birmingham kuma mai ba da shawara na girmamawa ga likitan ido ƙwararrun cututtukan ido kamar bushewar ido. A matsayin wani ɓangare na ƙwarewarta, Saaeha ƙwararriya ce a cikin yankunan Pemphigoid, Stevens-Johnson Syndrome da Sjogren's Syndrome duk tare da alamun bayyanar cututtuka da sakamako masu kama da EB. Ita ce PI kuma Babban Mai binciken na biyu na farko-cikin-dan Adam gwajin gel Phase I na asibiti na zubar ido. Don haka za ta kasance mai kima wajen fahimtar yanayin ido na shirin.

Mista Amit Patel mashawarcin likitan ido ne a Asibitocin Jami'ar NHS Trust. Yana ba da kulawar ido na yau da kullun ga ɗimbin ƙungiyar manya marasa lafiya tare da epidermolysis bullosa da aka gani a cikin rabin sabis na EB na ƙasa, tushen a cikin Trust. Don haka zai ba da haske mai yawa game da kulawar ido na haƙuri da kulawa na yau da kullun.

Mai haɗin gwiwa:

Dokta Holly Chinnery, Jami'ar Melbourne, Ostiraliya.

“Magudanun da ake amfani da su a halin yanzu suna kasancewa a kan ido na ɗan gajeren lokaci, ma'ana dole ne a yi amfani da su akai-akai a tsawon yini. A cikin wannan aikin, muna ƙoƙarin magance wannan matsala ta hanyar gabatar da sabon ƙwayar ido wanda aka nuna ya dade a saman ido. Wannan yana nufin cewa majiyyata suna buƙatar yin amfani da digon su akai-akai. A cikin dogon lokaci, waɗannan ɗigon ido na iya cika da kwayoyin halitta waɗanda zasu iya hana tabo daga faruwa. Muna fatan wannan zai samar wa marasa lafiya karin 'yanci da ingantaccen rayuwa."

– Farfesa Liam Grover

Taken Grant: Babban riƙewa, mai sa ido yana sauke don haɓaka ingancin rayuwa a cikin marasa lafiya na EB.

Ɗaya daga cikin illolin da ke tattare da nau'ikan EB da yawa shine lalacewa a saman idanu, wanda ya haifar da zubar da fatar ido a kan idon da ya riga ya damu. Wannan na iya haifar da ciwo, tabo da yiwuwar makanta. Lalacewar da wannan tsari ya haifar shine mummunan yanayin - lalacewa ga ido yana rage man shafawa, wanda ya sa ido ya fi dacewa da lalacewa.

A halin yanzu, likitocin suna ƙoƙarin karya zagayowar ta hanyar samar da ɗigon ido, wanda ke ba da damar murfin ido ya zazzage saman ido. Digon da ake amfani da shi a halin yanzu yakan kasance a kan ido na ɗan gajeren lokaci, ma'ana dole ne a yi amfani da su akai-akai a tsawon yini.

A cikin wannan aikin, muna ƙoƙarin magance wannan matsala ta hanyar gabatar da sabon ƙwayar ido wanda aka nuna ya dade a saman ido. Wannan yana nufin cewa majiyyata suna buƙatar yin amfani da digon su akai-akai. A cikin dogon lokaci, waɗannan ɗigon ido na iya cika da kwayoyin halitta waɗanda zasu iya hana tabo daga faruwa. Muna fatan wannan zai ba marasa lafiya ƙarin 'yanci da ingantaccen rayuwa.

Ayyukan da aka tsara na da mahimmanci kai tsaye ga marasa lafiya tare da kowane nau'i na epidermolysis bullosa (EB) mai yiwuwa su haɓaka bayyanar cututtukan ido na bushe, amma musamman dystrophic na recessive da junctional subtypes inda blistering / ulceration na ido saman ya fi kowa.

Wannan aikin zai sake yin amfani da fasahar ido-dop wanda a halin yanzu yake cikin ƙarshen matakan haɓakawa kuma ya sanya shi a shirye don jigilar manyan mutane zuwa marasa lafiya na EB tare da lalacewar ido. Wannan aikin zai ba da damar> £ 4m na saka hannun jari na majalisar bincike (MRC da NIHR) wanda ya ba mu damar haɓaka, ƙira, da tattara bayanan guba akan faɗuwar, don ba da damar gwaji na farko-cikin ɗan adam. A lokacin da aka fara aikin, za mu kammala gwajin lafiyar ɗan adam na farko tare da masu sa kai masu lafiya kuma za mu matsa zuwa kula da marasa lafiya masu fama da bushewar ido (NIHR) da ƙananan keratitis (MRC). Saboda wannan dalili, muna jin cewa aikin zai iya yin tasiri sosai ga marasa lafiya a cikin shekaru biyu.

Don cimma wannan, babban burin wannan aikin shine:

1. Tare da likitoci da ƙungiyoyin haƙuri, fahimtar buƙatun (cikin sharuddan cuta) da buƙatun samfurin ƙarshe, don samar da ingantaccen magani mai haɓaka rayuwa.
2. Fahimtar kimiyya mai tushe a bayan man shafawa da shafa tsakanin kyallen takarda a cikin kogon ido don hana kumburi.
3. Siffata da kwatanta idon ruwan gel ɗin da ke sauke zuwa zaɓuɓɓukan jiyya na yanzu dangane da lubricanci da riƙewa.
4. Ɗauki matakan da suka wajaba don sake rarraba digon ido daga samfurin likita zuwa na'urar likita.

Ƙungiyarmu tana gudanar da bincike don ƙarin fahimta da magance matsalolin ido a cikin mutane masu Epidermolysis Bullosa (EB). EB na iya rinjayar ido a hanya mai mahimmanci, tare da marasa lafiya da ke fama da rashin lafiya ga lalacewar corneal saboda rikici da rauni. A halin yanzu muna haɓaka digon idon mai mai da aka yi daga sigar kwayan cuta da ake kira gellan gum, wanda ke nuna alƙawarin ba da kariya daga lalacewar da ke da alaƙa da sel na cornea.

Ta hanyar nazarinmu, mun lura cewa zubar da ido na tushen gellan na iya taimakawa wajen hana fibrosis na ido-yanayin da tabo nama ke samuwa a saman cornea, wanda ke haifar da matsalolin hangen nesa. Ta hanyar daidaita adadin gellan danko a cikin ɗigon idonmu, za mu iya keɓance gel ɗin don kasancewa cikin sauƙin amfani yayin da ya dace da kiyayewa daga lalacewa mai alaƙa da gogayya ga sel na cornea. Wannan gyare-gyaren yana tabbatar da cewa gel zai iya kare sel masu laushi a kan farfajiyar corneal ba tare da haifar da rashin jin daɗi ba yayin aikace-aikacen.

Bincikenmu mai gudana yana nufin zurfafa zurfin fahimtar hanyoyin da ke tattare da tasirin kariya na digon ido na gellan danko don haɓaka jiyya na abokantaka don sarrafa alamun ido a cikin marasa lafiya na EB.

Muna godiya ga goyon bayan DEBRA UK da magoya bayanta, wanda ya ba mu damar yin amfani da wannan muhimmin bincike. (Daga rahoton ci gaba na 2024).